2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 66.614 | 48.090 | 240.278 | 79.069 | 23.560 | 38.224 | 107.915 | 573.034 | 840.905 | 1.313.269 |
Total Income - EUR | 66.627 | 48.092 | 241.370 | 79.103 | 24.394 | 38.286 | 107.915 | 575.092 | 841.700 | 1.401.301 |
Total Expenses - EUR | 62.573 | 43.667 | 236.308 | 75.731 | 31.778 | 27.895 | 96.609 | 538.935 | 653.210 | 1.343.883 |
Gross Profit/Loss - EUR | 4.055 | 4.425 | 5.062 | 3.373 | -7.384 | 10.391 | 11.306 | 36.157 | 188.490 | 57.418 |
Net Profit/Loss - EUR | 2.899 | 3.686 | 2.648 | 1.133 | -7.632 | 10.170 | 10.227 | 30.408 | 168.949 | 47.807 |
Employees | 4 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 0 | 1 |
Check the financial reports for the company - Biocomprest Srl
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 11.187 | 10.097 | 8.200 | 6.909 | 5.657 | 5.550 | 5.351 | -778 | 580 | 0 |
Current Assets | 55.541 | 55.149 | 73.757 | 31.326 | 27.477 | 53.518 | 146.345 | 497.994 | 668.965 | 2.253.583 |
Inventories | 21.256 | 27.002 | 56.195 | 17.442 | 17.319 | 31.072 | 31.374 | 408.533 | 96.573 | 717.023 |
Receivables | 29.278 | 26.440 | 15.068 | 11.627 | 8.146 | 20.458 | 108.722 | 71.799 | 567.961 | 1.501.915 |
Cash | 5.007 | 1.707 | 2.494 | 2.256 | 2.012 | 1.988 | 6.248 | 17.662 | 4.431 | 34.645 |
Shareholders Funds | 26.341 | 29.758 | 31.906 | 32.451 | 24.191 | 33.902 | 23.489 | 199.990 | 469.840 | 1.159.955 |
Social Capital | 450 | 445 | 438 | 430 | 421 | 413 | 404 | 406 | 404 | 2.000 |
Debts | 40.386 | 40.164 | 50.050 | 5.785 | 8.943 | 25.166 | 128.207 | 297.225 | 199.705 | 1.095.590 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 1 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
Main CAEN | "4532 - 4532" | |||||||||
CAEN Financial Year |
4120
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Biocomprest Srl